Patient-Reported Outcomes Instruments Need Validation Before Pivotal Trials
Patient-reported outcomes instruments should be validated prior to use in a pivotal clinical trial, FDA Antimicrobial Drug Development & Resistance Initiatives Lead Medical Officer John Powers told a Drug Information Association webinar on FDA's PRO draft guidance April 5
More from Archive
More from Pink Sheet
The Center for Biologics Evaluation and Research saw departures far outnumber new hires in the second and third quarters of FY 2025, before more than 100 people left July 14 after the reduction-in-force was finalized.
US FDA's cancer drugs division is feeling the effect of drug reviewer departures, despite efforts to keep them at the agency.
Reforming clinical trial regulations, addressing the use of artificial intelligence, mitigating medicines shortages and strengthening ties with other drug regulators are key priorities for Australia’s Therapeutic Goods Administration over the next year.